Is GRCE or CNTB more profitable?

Grace Therapeutics' return on equity of -15.58% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Connect Biopharma N/A -122.29% -97.07%

Does the media prefer GRCE or CNTB?

In the previous week, Grace Therapeutics and Grace Therapeutics both had 2 articles in the media. Connect Biopharma's average media sentiment score of 1.68 beat Grace Therapeutics' score of 1.17 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, GRCE or HURA?

Grace Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is GRCE or HURA more profitable?

Grace Therapeutics' return on equity of -15.58% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% TuHURA Biosciences N/A -156.12% -105.38%

Does the media prefer GRCE or HURA?

In the previous week, TuHURA Biosciences had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat TuHURA Biosciences' score of -0.05 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, GRCE or CRDL?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is GRCE or CRDL more profitable?

Grace Therapeutics' return on equity of -15.58% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Cardiol Therapeutics N/A -229.43% -165.60%

Does the media refer more to GRCE or CRDL?

In the previous week, Grace Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Cardiol Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Cardiol Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CRBP or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A

Is CRBP or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Grace Therapeutics N/A -15.58% -14.51%

Does the media prefer CRBP or GRCE?

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Corbus Pharmaceuticals' score of 0.61 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GNLX or GRCE more profitable?

Grace Therapeutics' return on equity of -15.58% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Grace Therapeutics N/A -15.58% -14.51%

Does the media favor GNLX or GRCE?

In the previous week, Genelux and Genelux both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.17 beat Genelux's score of 0.91 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grace Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grace Therapeutics (GRCE) Competitors

$2.40 -0.05 (-1.84%)

Closing price 03:58 PM Eastern

Extended Trading

$2.42 +0.02 (+0.62%)

As of 05:32 PM Eastern

Compare

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include Connect Biopharma (CNTB), TuHURA Biosciences (HURA), Cardiol Therapeutics (CRDL), Corbus Pharmaceuticals (CRBP), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

How does Grace Therapeutics compare to Connect Biopharma?

Grace Therapeutics (NASDAQ:GRCE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Grace Therapeutics' return on equity of -15.58% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Connect Biopharma	N/A	-122.29%	-97.07%

Grace Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 149.48%. Connect Biopharma has a consensus price target of $7.20, suggesting a potential upside of 213.04%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Grace Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Grace Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Connect Biopharma	$60K	2,413.47	-$55.48M	-$1.15	N/A

In the previous week, Grace Therapeutics and Grace Therapeutics both had 2 articles in the media. Connect Biopharma's average media sentiment score of 1.68 beat Grace Therapeutics' score of 1.17 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Connect Biopharma beats Grace Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to TuHURA Biosciences?

Grace Therapeutics (NASDAQ:GRCE) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 149.48%. TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 310.96%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, TuHURA Biosciences had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat TuHURA Biosciences' score of -0.05 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Grace Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Grace Therapeutics' return on equity of -15.58% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Summary

Grace Therapeutics beats TuHURA Biosciences on 8 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Cardiol Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Grace Therapeutics' return on equity of -15.58% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Grace Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Grace Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Cardiol Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Cardiol Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Grace Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 149.48%. Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 639.13%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cardiol Therapeutics beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

Corbus Pharmaceuticals currently has a consensus price target of $42.00, indicating a potential upside of 425.00%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 149.48%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Grace Therapeutics' return on equity of -15.58% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Grace Therapeutics	N/A	-15.58%	-14.51%

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.17 beat Corbus Pharmaceuticals' score of 0.61 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corbus Pharmaceuticals beats Grace Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Genelux and Genelux both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 1.17 beat Genelux's score of 0.91 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grace Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

37.3% of Genelux shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grace Therapeutics has lower revenue, but higher earnings than Genelux. Grace Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,810.72	-$32.15M	-$0.85	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 484.42%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 149.48%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -15.58% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Grace Therapeutics	N/A	-15.58%	-14.51%

Summary

Genelux beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.21M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-6.01	18.78	23.87	24.36
Price / Sales	N/A	320.80	521.52	117.06
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.49	6.80	9.99	6.73
Net Income	-$9.57M	$24.09M	$3.56B	$337.03M
7 Day Performance	-1.03%	-2.56%	-0.90%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-16.49%	48.90%	28.77%	33.98%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.6709 of 5 stars	$2.41 -1.8%	$6.00 +149.5%	-13.1%	$37.21M	N/A	N/A	N/A	News Coverage
CNTB Connect Biopharma	3.9053 of 5 stars	$2.49 +4.6%	$7.20 +189.2%	+175.0%	$149.85M	$60K	N/A	110	Insider Trade
HURA TuHURA Biosciences	1.886 of 5 stars	$2.26 -3.8%	$9.00 +298.2%	-27.6%	$149.65M	N/A	N/A	N/A	Analyst Revision Gap Down
CRDL Cardiol Therapeutics	2.3585 of 5 stars	$1.22 -4.7%	$8.50 +596.7%	-14.5%	$143.13M	N/A	N/A	20	Positive News
CRBP Corbus Pharmaceuticals	4.5243 of 5 stars	$7.91 +3.5%	$42.00 +431.0%	-11.1%	$141.55M	N/A	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

How does Grace Therapeutics compare to Connect Biopharma?

Summary

How does Grace Therapeutics compare to TuHURA Biosciences?

Summary

How does Grace Therapeutics compare to Cardiol Therapeutics?

Summary

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Summary

How does Grace Therapeutics compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. CNTB, HURA, CRDL, CRBP, and GNLX

How does Grace Therapeutics compare to Connect Biopharma?

Do institutionals and insiders have more ownership in GRCE or CNTB?

Is GRCE or CNTB more profitable?

Which has more risk & volatility, GRCE or CNTB?

Do analysts recommend GRCE or CNTB?

Which has preferable valuation and earnings, GRCE or CNTB?

Does the media prefer GRCE or CNTB?

Summary

How does Grace Therapeutics compare to TuHURA Biosciences?

Do analysts prefer GRCE or HURA?

Does the media prefer GRCE or HURA?

Do institutionals & insiders believe in GRCE or HURA?

Which has stronger valuation and earnings, GRCE or HURA?

Which has more risk and volatility, GRCE or HURA?

Is GRCE or HURA more profitable?

Summary

How does Grace Therapeutics compare to Cardiol Therapeutics?

Is GRCE or CRDL more profitable?

Do institutionals & insiders hold more shares of GRCE or CRDL?

Which has more volatility and risk, GRCE or CRDL?

Does the media refer more to GRCE or CRDL?

Which has preferable valuation & earnings, GRCE or CRDL?

Do analysts recommend GRCE or CRDL?

Summary

How does Grace Therapeutics compare to Corbus Pharmaceuticals?

Which has better valuation & earnings, CRBP or GRCE?

Do analysts rate CRBP or GRCE?

Do institutionals and insiders hold more shares of CRBP or GRCE?

Which has more risk and volatility, CRBP or GRCE?

Is CRBP or GRCE more profitable?

Does the media prefer CRBP or GRCE?

Summary

How does Grace Therapeutics compare to Genelux?

Does the media favor GNLX or GRCE?

Do institutionals & insiders have more ownership in GNLX or GRCE?

Which has stronger valuation and earnings, GNLX or GRCE?

Which has more risk and volatility, GNLX or GRCE?

Do analysts recommend GNLX or GRCE?

Is GNLX or GRCE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools